Gulnar Rakhimbekova

Gulnar Rakhimbekova

Auto-generated profile, based on publicly available information

Gulnar Rakhimbekova

Department of Medicine, Astana Medical University, Astana 010000, Kazakhstan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GRGalymzhan Ryskulov
Galymzhan Ryskulov
MAMalik Adenov
Malik Adenov
MZMaira Zhaparkulova
Maira Zhaparkulova
ABAlibek Bissembayev
Alibek Bissembayev
GRGulnar Rakhimbekova
Gulnar Rakhimbekova
MSMarat Shoranov
Marat Shoranov
Background: Tuberculosis (TB) remains a major public health concern globally, despite sustained declines in incidence in many countries. Kazakhstan has implemented long-term national TB control strategies; however, comprehensive nationwide analyses integrating temporal trends, demographic patterns, and treatment outcomes over the past decade remain limited. Methods: A nationwide retrospective registry-based analysis of programmatic TB treatment episodes was conducted using anonymized data from the national tuberculosis registry of the Ministry of Health of Kazakhstan. All registered TB cases from 1 January 2014 to 31 December 2023 were included. Treatment outcome was analyzed as the final end-of-episode programmatic status (favorable vs. unfavorable). Because the anonymized extract did not contain complete patient-level dates required to derive person-time (treatment initiation and event dates), time-to-event models were not applied; instead, factors associated with unfavorable end-of-treatment outcomes were assessed using multivariable logistic regression and reported as adjusted odds ratios (aORs) with 95% CIs. Unfavorable treatment outcomes were defined as death, treatment failure, loss to follow-up, and not evaluated or not recorded outcome, according to the national TB program outcome definitions. Results: A total of 93,985 TB cases were analyzed. The number of registered cases declined from 16,391 in 2014 to 6548 in 2023, corresponding to a cumulative reduction of 60.1% and an AAPC of −9.7% per year. TB incidence decreased in both sexes, although rates remained consistently higher among men. Over time, the peak incidence shifted toward older age groups, particularly among men. The proportion of new cases increased to 80.1% by 2023, while relapses and treatment failures declined. In multivariable analysis, unfavorable treatment outcomes were independently associated with male sex (aOR 1.25), older age, relapse, treatment after interruption, prior treatment failure, smear-positive disease (aOR 1.60), combined pulmonary and extrapulmonary involvement, and disseminated TB (ICD-10 A19). The risk of unfavorable outcomes increased during 2020–2021 and declined in 2022–2023. Conclusions: Kazakhstan has achieved a substantial and sustained reduction in TB incidence over the past decade. Nevertheless, marked demographic and clinical disparities persist, particularly among men, older patients, smear-positive cases, and individuals with prior or interrupted treatment. Targeted interventions focused on these high-risk groups may further improve treatment outcomes and support continued progress toward TB control.

8 January 2026 in Life
Verified
Journal Article
Open access
PDF file
TFTimur Fazylov
Timur Fazylov
TSTimur Saliev
Timur Saliev
Igor DankoIgor Danko
Igor Danko
ZBZhomart Beksultanov
Zhomart Beksultanov
STShynar Tanabayeva
Shynar Tanabayeva
MSMarat Shoranov
Marat Shoranov
Background. Acute radiation injury to the small-intestinal mucosa and the hematopoietic system is a key determinant of early mortality after high-dose total-body irradiation. ε-Aminocaproic acid (EACA), a lysine analogue with antifibrinolytic properties, has been proposed as a potential radioprotective agent, but its effects on intestinal and hematologic injury remain insufficiently characterized. Methods. In this experimental study, 240 male Wistar rats were subjected to single-dose total-body γ-irradiation at 10.6 Gy and randomized into six groups: two non-irradiated controls (CG-1, CG-2), an irradiated control without treatment (CG-3), and three experimental groups receiving EACA (EG-1: 3 h before irradiation; EG-2: 3 h after irradiation; EG-3: both 3 h before and 3 h after irradiation). Pain behavior was assessed using the Rat Grimace Scale. Intestinal damage was evaluated by a modified Radiation Injury Intestinal Mucosal Damage Score (RIIMS_sum), villus and crypt morphometry, and qualitative histology of the ileum. Hemoglobin, leukocytes, and platelets were measured serially, and 30-day survival was analyzed using Kaplan–Meier curves with log-rank tests. Results. Across all EACA regimens, the odds of being in a higher Rat Grimace Scale pain category were reduced compared with CG-3, with the strongest effect in EG-3 (OR 0.42; 95% CI 0.31–0.58). At 72 h after irradiation, the cumulative RIIMS score was lower in EACA-treated groups by approximately 17–36% versus CG-3, with the lowest injury in EG-3 (18.5 vs. 29.0 points). EACA attenuated shortening and blunting of villi, preserved crypt architecture, and mitigated anemia, leukopenia, and thrombocytopenia. Thirty-day survival was 20% in CG-3 and 60%, 65%, and 80% in EG-1, EG-2, and EG-3, respectively (all p < 0.05 vs. CG-3). Conclusions. ε-Aminocaproic acid exerts a pronounced, timing-dependent radioprotective effect in a rat model of acute total-body γ-irradiation, concurrently reducing the severity of radiation enteritis, hematologic toxicity, and early mortality. These findings support further investigation of EACA as a candidate adjunct in the prevention of acute radiation injury.